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Introduction
The TNF-like cytokines B cell–activating factor (BAFF) and a proliferating ligand (APRIL) are important 
regulators of  B cell survival and function. The physiologic effects of  BAFF and APRIL are influenced 
by the availability of  the individual cytokines in each microenvironment, the relative expression of  the 3 
receptors, BAFF-R, transmembrane activator and CAML interactor (TACI), and B cell maturation antigen 
(BCMA) on each B cell subset, and differences in receptor binding specificity and downstream signaling 
pathways of  the 2 cytokines (1, 2).
BAFF excess causes lupus-like autoreactivity by several proposed mechanisms. First, the binding of  
BAFF to BAFF-R cooperates with BCR signaling to set the threshold for selection of  transitional B cells 
(3). Second, the binding of  BAFF to TACI promotes the selection and T cell–independent differentiation 
of  a subpopulation of  autoreactive B cells that may include transitional B cells and/or B1b B cells (4–6). 
Third, BAFF-mediated signals augment the B cell expression of  endosomal Toll-like receptors (TLRs) 
and rescue B cells from death mediated by TLR9 signals, thereby amplifying immune responses to nucleic 
acids and regulating B cell tolerance to DNA (7, 8). In the germinal center milieu, BAFF produced by T 
follicular helper cells enhances the selection of  high-affinity germinal center B cells via its binding to TACI 
(9), whereas in the extrafollicular milieu and bone marrow both BAFF and APRIL support plasma cell 
survival via binding to TACI and BCMA (9–11). Finally, BAFF regulates inflammation through its effects 
on cytokine release by antigen-presenting cells (12). Conversely, BAFF deficiency delays the onset of  lupus 
through mechanisms that may include altered B cell selection, B cell depletion, and decreased target organ 
inflammation (13–18).
Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially in 
patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss in 
belimumab-treated SLE patients is accompanied by shifts in the immunoglobulin repertoire. We 
enrolled 15 patients who had been continuously treated with belimumab for more than 7 years, 
17 matched controls, and 5 patients who were studied before and after drug initiation. VH genes 
of sort-purified mature B cells and plasmablasts were subjected to next-generation sequencing. 
We found that B cell–activating factor (BAFF) regulates the transitional B cell checkpoint, with 
conservation of transitional 1 (T1) cells and approximately 90% loss of T3 and naive B cells after 
chronic belimumab treatment. Class-switched memory B cells, B1 B cells, and plasmablasts were 
also substantially depleted. Next-generation sequencing revealed no redistribution of VH, DH, or 
JH family usage and no effect of belimumab on representation of the autoreactive VH4-34 gene or 
CDR3 composition in unmutated IgM sequences, suggesting a minimal effect on selection of the 
naive B cell repertoire. Interestingly, a significantly greater loss of VH4-34 was observed among 
mutated IgM and plasmablast sequences in chronic belimumab–treated subjects than in controls, 
suggesting that belimumab promotes negative selection of activated autoreactive B cells.
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The human anti-BAFF antibody belimumab is therapeutic for active systemic lupus erythematosus 
(SLE), especially in patients with high titers of  anti-dsDNA antibodies and low serum levels of  comple-
ment (19–23). Belimumab has modest and variable effects on anti-DNA antibody synthesis; however, it 
has not yet been shown in humans whether the basis of  its therapeutic effect is an alteration in selection of  
either the naive or antigen-induced immunoglobulin repertoire. The current study was designed to address 
whether the profound loss of  B cells in belimumab-treated patients is accompanied by a shift in the immu-
noglobulin repertoire of  either mature B cells or plasma cells.
Results
Human subjects. The demographic characteristics of  the SLE patients and controls are shown in Table 1. There 
were no differences between the belimumab-treated patients and the SLE controls except in disease duration, 
which was slightly shorter in the lupus controls (P < 0.05). Patients receiving belimumab chronically and 
lupus controls had quiescent disease with limited use of  immunosuppressive medications. Patients with active 
disease newly starting on belimumab were on significantly higher doses of  prednisone than either the patients 
on chronic belimumab or the lupus controls (P < 0.001 and P < 0.0001, respectively).
B cell phenotype. The gating strategy for B cell phenotyping is shown in Supplemental Figure 1 (sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.122525DS1). 
Patients receiving chronic belimumab had an average depletion of  88% of  all B cells compared with SLE 
controls (Figure 1, A and B). In agreement with our previous study (24), not all B cell subsets were depleted 
to the same degree, resulting in a redistribution of  B cell subsets. Mature CD27–IgD+ B cells constituted a 
lower percentage and class-switched memory B cells a higher percentage of  the remaining B cells. Class-
switched memory B cells and B1 cells are BAFF independent and take longer to deplete after belimumab 
treatment than naive B cells (10, 24, 25) (Supplemental Figure 2). Nevertheless, memory subsets were 
significantly depleted in the peripheral blood after long-term belimumab treatment (Figure 1, C and D) as 
were plasmablasts and B1 cells (Figure 1, E and F), although to a lesser degree than memory cells.
To investigate how BAFF regulates the early development of human B cells, we utilized the ABCB1 trans-
porter and other B cell developmental markers (26–29) to rigorously separate CD27–IgD+ B cells into their differ-
ent subsets (Supplemental Figure 1). We found no difference in the number of transitional 1 (T1) B cells between 
chronic belimumab–treated patients and lupus controls. By contrast, there was 79% deletion of the T2 subset 
and 93% deletion of the T3 subset (Figure 2, A and B). Similarly, patients newly treated with belimumab had 
lost most of their T3 cells by the 6-month visit (7 treatments) while retaining their T1 cells (Supplemental Figure 
2). Notably, a large population of circulating T1 cells was detected in 5 chronic belimumab–treated patients, 
constituting from 11% to 60% of surviving B cells. A large population of T1 cells was similarly observed at the 
6-month visit in the 1 patient that had a large number of T1 cells (0.75% of all B cells) at the initial visit (Supple-
mental Figure 2). These data suggest that the high T1 cell number observed in a subset of chronically treated 
patients reflects a high starting number of T1 cells that are unaffected by belimumab treatment.
CD24+ activated naive B cells that fail to extrude MitoTracker Green (MTG+) are clonally related 
to antibody-secreting cells, contain mutated immunoglobulin genes, and contribute to the autoanti-
body repertoire in active SLE patients (29). We found that these cells were depleted to the same degree 
as late transitional and naive B cells (Figure 2, A and B, and Supplemental Figure 2). In addition, the 
MTG+CD24+CD38+ subpopulation whose function is not documented (28) was present in both healthy 
donors and lupus controls and was depleted by 93% in belimumab-treated patients, similar to the naive 
population (Figure 2, A and B, and Supplemental Figure 2).
Signaling through the Fas receptor is an important mechanism for apoptosis of  autoreactive B cells 
(30, 31). Fas expression was lower in naive B cells than in the other subsets, with no differences between 
belimumab-treated subjects and lupus controls or healthy donors in the naive or memory compartments. 
Unexpectedly, significantly more B-1 B cells from chronic belimumab–treated patients expressed Fas than 
from lupus controls or healthy donors, with a trend towards a difference for double-negative (DN) B cells 
(LC vs. CB, P < 0.08; Supplemental Figure 3A). No differences were observed, however, when comparing 
the paired pre- and posttreatment samples.
CD21lo B cells are frequent in autoimmune patients and can be found in multiple B cell compartments 
including the DN compartment and the overlapping subset of  age-associated B cells that are induced in 
inflammatory conditions (32, 33). No differences were observed in the frequencies of  CD21lo B cells in any 
B cell subset between chronic belimumab–treated subjects and the other groups (Supplemental Figure 3B), 
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as the reductions of  CD21lo B cells were similar across observed populations (Supplemental Figure 3C). 
Similarly, although CD21lo B cells decreased in subjects newly treated with belimumab (Supplemental Fig-
ure 2), no changes in the frequencies of  CD21lo cells per subset were observed.
VH repertoire of  unmutated IgM sequences from mature B cells. Naive B cells from healthy subjects are 
reported to have an increased ratio of  VH1/VH3, increased expression of  IgHD3, and an increase in the 
ratio of  JH4/JH6 compared with transitional B cells (34), reflecting selection at this checkpoint. These 
changes were not exaggerated in the unmutated IgM sequences from chronic belimumab–treated patients 
compared with lupus controls (Supplemental Figure 4, A, C, and E) or between pre- and post-belimumab 
samples from 5 subjects (Supplemental Figure 4, B, D, and F). At the individual VH gene level, naive B 
cells from healthy subjects express more VH1-69 and 5-51 and less VH3-30 than transitional cells (34). We 
observed an increase in VH1-69, VH2-26, and VH3-15 expression in chronic belimumab–treated patients 
compared with lupus controls (raw P values < 0.05), although not in the posttreatment versus pretreatment 
samples (Figure 3, A and B). However, these changes did not reach statistical significance after correcting 
for multiple comparisons. Furthermore, using Simpson’s diversity index, we found no difference in clonal 
diversity between the 2 groups (Supplemental Table 2 and Supplemental Figure 5A).
Certain VH region genes are known to encode for autoreactivity in their germline configuration. Of these, 
VH4-34, which is negatively selected from the memory and plasmablast compartments of healthy individuals, 
is overrepresented among activated naive B cells as well as among memory B cells and plasmablasts of lupus 
Figure 1. Most B cell subsets are depleted after chronic belimumab therapy. PBMCs from healthy donors (n = 13), lupus controls (n = 17), and chronic 
belimumab–treated subjects (n = 15) were stained with a cocktail of antibodies (Supplemental Table 1 – Panel 1) and analyzed by flow cytometry. Cells 
were gated as shown in Supplemental Figure 1. (A and B) Plots display frequency (A) and absolute cell count/ml (B) of CD19+ B cells in gated live singlet 
lymphocytes. (C–F) Plots display frequency (C and E) and absolute cell count/ml (D and F) of major B cell subsets in gated CD19+ B cells. Average percent-
age depletion of each cell subset compared with lupus controls is shown above the plots. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not 
significant. Comparisons were performed using Kruskal-Wallis test (A, C, and E) and Mann-Whitney analysis (B, D, and F).
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patients (29, 35–37). VH4-34 was expressed in 4% of the naive B cell repertoire from lupus controls and was 
not preferentially deleted in the unmutated sequences of chronic belimumab–treated patients (Figure 3, A and 
B). Similarly, there was no significant decrease in its representation among unmutated IgM sequences 6 months 
after belimumab initiation in 5 newly treated patients (Supplemental Figure 4, G–K).
These data in sum show that the approximately 90% depletion of  naive B cells found after belimumab 
treatment involves B cells encoded by virtually all VH genes without preferential deletion or enrichment of  
a particular VH.
Figure 2. Belimumab regulates survival of B cells as they transition from the T1 stage to the naive phenotype. Mature B cells were stained with a 
cocktail of antibodies (Supplemental Table 1 – Panel 2), and gated as shown in Supplemental Figure 1. Cells were subsetted on the basis of CD24 and CD38 
expression and the ability to extrude MitoTracker Green (MTG). (A and B) Plots display frequency (A) and absolute cell count/ml (B) of transitional type 1 
(T1), T2, T3, naive, activated naive (29), and MTG+CD24+CD38– subsets in gated CD19+ B cells. The number of subjects in each group was healthy donor (n = 
13), lupus control (n = 14), chronic belimumab (n = 14). (C and D) Pseudocolor plots showing changes in B cell subsets of a representative lupus donor before 
(C) and after (D) belimumab therapy. Samples with fewer than 200 total B cells collected were excluded from some of the subset analyses due to insuffi-
cient cells in the subgates. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant. Comparisons were performed using Kruskal-Wallis test 
(A) and Mann-Whitney analysis (B).
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The heavy chain D region makes an important contribution to antigen specificity, and particular charged 
amino acids, especially arginine (R), have been shown to confer specificity for dsDNA (38, 39). No particular 
pattern of CDR3 amino acid distribution distinguished chronic belimumab–treated patients from lupus controls. 
Similarly, when we examined pre- and post-belimumab samples, sequential samples from individual subjects 
clustered together regardless of their treatment status (Figure 3C). Among a reference set of autoreactive single 
cells isolated from naive and immature B cells of healthy donors and lupus patients (40–42), those binding 
Figure 3. VH repertoire of unmutated IgM sequences from mature B cells. (A) Frequency of VH usage of the functional unmutated IgM repertoire from SLE 
patients treated with chronic belimumab (CB, blue) and lupus controls (LC, green) is shown. Each data point represents an individual subject. Heatmaps show 
the average frequency of VH-JH paired usage of LC and CB groups (B, left and right, respectively). (C) Clustered heatmap shows the amino acid usage of the 
CDR3 from LC, CB, reference non-autoreactive, and ANA-reactive groups, and of 5 individuals before (Pre) and 6 months after (Post) belimumab treatment. 
Distribution of CDR3 physicochemical properties (acidic [D], basic [E]) for LC and CB groups compared with the reference non-autoreactive and ANA-reactive 
groups. **P < 0.01; ns, not significant (linear mixed model). (F) Distribution of CDR3 amino acid length usage of LC (green) and CB (blue) groups. (G) Principle 
component analysis (PCA) of Kidera factors. For A, D, and F, the number of subjects in each group was LC (n = 12) and CB (n = 15).
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dsDNA had a significant increase in basic residues H, K, and R and a decrease in acidic residues D and E com-
pared with non-autoreactive cells. We found a statistically significant decrease in acidic residues in the CDR3 
of belimumab-treated subjects compared with lupus controls, contrary to what would be expected, but no dif-
ference in basic residues (Figure 3, D and E). When this analysis was restricted to VH4-34–encoding sequences, 
no differences were found either in acidic or basic residues. It has been further suggested that longer heavy chain 
CDR3 length contributes to polyreactivity (40, 43). We found no change in the CDR3 length of sequences in 
patients treated with chronic belimumab compared with lupus controls (Figure 3F). We next examined the 
biophysical features of the CDR3 regions using Kidera factors that reduce over 100 different biophysical charac-
teristics of peptides into 10 independent factors (44). We found no difference in any of the tested characteristics 
of the CDR3 regions in belimumab-treated subjects compared with lupus controls when we examined all factors 
individually or together (Figure 3G). Similarly, no changes in acidic or basic residues or in Kidera factors were 
observed in unmutated IgM sequences of 5 subjects examined before and after belimumab treatment. One char-
acteristic of B cell selection is the loss of hydrophobicity in CDR3 between transitional and mature recirculating 
B cells (45). Using either Boman’s index or Kidera factors, we found no differences in hydrophobicity between 
chronic belimumab–treated subjects and lupus controls or between pre- and posttreatment samples (Figure 3G).
VH repertoire of  mutated IgM sequences from mature B cells. Mutated IgM sequences derived from CD27– B 
cells provide a window into the antigen-selected B cell repertoire that includes activated naive B cells. The 
repertoire of  these cells was clearly different from that of  their low-mutated counterparts both in lupus 
controls and in chronic belimumab–treated subjects, with strikingly similar alterations in the landscape 
of  VH genes in both groups (Figure 4, A and B, and Supplemental Table 3). Compared with unmutated 
mature B cells, there was loss of  VH4-34 among mutated IgM sequences in both lupus controls and chronic 
belimumab–treated subjects; after correcting for multiple comparisons, this loss was only significant in the 
belimumab-treated subjects (37% ± 9% loss vs. 21% ± 15%, P < 0.001; Figure 5C). No consistent changes 
were found, however, between pre- and post-belimumab samples from the 5 newly treated subjects (Supple-
mental Figure 4, G–K). There were no significant differences in length, amino acid composition, hydropho-
bicity, or biophysical characteristics of  the CDR3 regions between mutated IgM sequences of  belimumab-
treated patients compared with lupus controls, or between pre- and posttreatment samples (Figure 5, D–F).
Two of  the 14 belimumab-treated subjects had clonal expansions within the mutated IgM sequences, 
only some of  which were shared with the plasmablast sequences (Supplemental Table 2 and Supplemental 
Figure 5B). In one of  these patients, a VH4-34 clone was present but was not shared with the plasmablast 
compartment from the same patient. There were no differences in clonal diversity of  mutated IgM sequenc-
es between the pre- and posttreatment samples (Supplemental Table 2 and Supplemental Figure 5C).
VH repertoire of  plasmablasts. Sufficient cells were recovered from 7 lupus controls and 13 belimumab-
treated subjects to examine the repertoire and clonal diversity of  plasmablasts. The repertoire of  these cells 
differed from that of  both unmutated and mutated IgM B cells in the chronic belimumab group (Figure 4, 
C and D, and Supplemental Table 3); because of  the small number of  subjects with matched samples, we 
may not have had enough power to detect differences in the lupus control group. Representation of  VH4-34 
was lower among plasmablasts than among matched unmutated IgM sequences in the chronic belimumab–
treated group, but did not differ from mutated IgM B cells (Figure 4, C and D, and Figure 5, A and B).
Plasmablasts manifested clonal expansion similar to that previously reported for SLE patients (29); the 
degree of  clonality of  the plasmablast repertoire was variable in both groups, with no differences between 
the lupus control and chronic belimumab–treated groups (Supplemental Table 2 and Supplemental Figure 
5D). We also asked whether the repertoire of  the most overrepresented clones differed between belim-
umab and control subjects, but there were no differences between groups. In contrast to previous observa-
tions in highly active SLE patients (29), VH4-34 contributed only 2%–3% of  the plasmablast repertoire in 
either group, perhaps reflecting the inactive status of  the patients in our cohort (Supplemental Figure 6 and 
Supplemental Figure 7, A and B). Nevertheless, anti-DNA antibodies were still present in the serum of  
the belimumab-treated patients, with variable changes in the levels of  these antibodies compared with the 
pre-belimumab values (Supplemental Figure 7C). The biophysical properties of  the CDR3 regions of  the 
plasmablast sequences from both belimumab-treated subjects and lupus controls were clearly different from 
those of  unmutated and mutated IgM, but not different from each other. This difference was accounted 
for mainly by an increase in polar and charged residues, both acidic and basic, in the CDR3 regions of  the 
plasmablasts (Figure 5, D–F).
7insight.jci.org   https://doi.org/10.1172/jci.insight.122525
R E S E A R C H  A R T I C L E
Discussion
This study extends our knowledge of  the effects of  BAFF inhibition on the survival and selection of  human 
B cells. We show here that BAFF regulates the checkpoint between transitional B cell stage 1 and transitional 
stage 3 in humans, with conservation of  transitional type 1 cells and approximately 90% loss of  transitional 
type 3 and naive B cells after chronic belimumab treatment. Despite the known expression of  BAFF-R on T1 
cells (28, 46), BCR- and BAFF-mediated signals are not well integrated in these cells and they manifest low 
BAFF responsiveness, making them less sensitive to changes in BAFF availability. This is similar to what has 
been reported in mouse T1 cells (47, 48). We examined naive activated B cells and CD21lo B cells that have 
a phenotype that overlaps with the recently described age-associated B cell subset, and that can give rise to 
autoreactive plasmablasts in response to innate B cell signals such as endosomal TLR ligands (32, 33). Nei-
ther subset was preferentially depleted by belimumab compared with naive B cells, suggesting that these cells 
require BAFF but do not have a generally increased BAFF requirement compared with the naive population. 
We found that the increase in CD27+ class-switched cells observed early after belimumab treatment is due to 
an increase in class-switched memory B cells rather than B1 cells. After more than 7 years of  treatment, there 
was a substantial loss of  BAFF-independent subsets, such as class-switched memory B cells, B1 B cells, and 
plasmablasts; this may reflect the failure to replenish these cells over time as naive B cells are lost.
In T cell–dependent responses, both CD40 ligation and FDC exposure in the germinal center enhance 
expression of  Fas, thus priming B cells for death; however, these cells can be rescued by strong BCR or 
costimulatory signals (49, 50). The interaction of  BAFF with BAFF-R can similarly protect B cells from 
Fas-mediated apoptosis and may therefore rescue low-affinity B cells from death (51). On the other hand, 
the interaction of  BAFF with TACI in innate B cells has been reported to facilitate upregulation of  both 
Fas and FasL on B cells and render them more susceptible to Fas-mediated apoptosis by downregulat-
ing inhibitors of  the apoptotic pathway (52). While there was no change in Fas expression in naive and 
class-switched memory B cells, we observed an increase in the percentage of  Fas-expressing B1 B cells and 
Figure 4. VH repertoire of mutated mature IgM sequences and plasmablasts. Changes in the VH usage of mutated 
mature (Mut) versus unmutated mature (Mat) IgM sequences of individual lupus control (LC) (n = 12) and chronic 
belimumab (CB) patients (n = 14) are shown as ratios in A and B, respectively. Each dot represents one patient. Changes 
in the VH usage of plasmablast (PB) versus unmutated mature (Mat) of and mutated mature (Mut) of individual CB 
patients are shown as ratios in C and D, respectively. Only those VH with statistically significant differences performed 
using a linear mixed model with crossing between cell populations and treatment groups to look for interactions are 
shown (see Supplemental Table 3).
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DN B cells in chronic belimumab–treated patients compared with controls; these subsets are thought to 
represent T cell–independent B cells. This finding is puzzling and could reflect either a difference in how 
BAFF regulates FasL expression in these cells or the failure to downregulate apoptotic inhibitors in a low-
BAFF environment, thus protecting the cells from Fas-mediated death when other B cells are diminished. 
Whether these cells are a source of  the plasmablasts that continue to be generated in belimumab-treated 
subjects remains to be determined.
One explanation for the therapeutic efficacy of BAFF inhibition is counterselection of autoreactive B cells. 
While extreme BAFF overexpression in mouse models is associated with altered selection of the naive B cell rep-
ertoire and/or induction of autoimmunity driven by T cell–independent B cells (4, 53, 54), studies of lupus mice 
bearing autoreactive V region transgenes have revealed variability in the response to BAFF antagonists, espe-
Figure 5. VH4-34 and CDR3 usage across groups. Frequency of VH4-34 in each subset for (A) lupus control (LC) (n = 6–8) and (B) chronic belimumab (CB) 
(n = 13) patients are shown in connected dot plots, with each line representing 1 patient. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. Compari-
sons were performed using Wilcoxon’s rank-sum test. (C) Plot displays the percentage reduction of VH4-34 usage in mutated mature B cells compared 
with unmutated mature B cells. Comparisons were performed using Mann-Whitney analysis. (D) Clustered heatmap shows the amino acid usage of the 
CDR3 from unmutated, mutated, and plasmablast (PB) sequences of LC and CB compared with reference non-autoreactive and autoreactive sequences. (E 
and F) Principle component analysis (PCA) of CDR3 amino acid composition (E) and physicochemical properties (Kidera factors, F) are shown for unmu-
tated, mutated, and PB sequences.
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cially when there is physiologic competition from non-autoreactive B cells (13). We have shown in lupus-prone 
mice that negative selection of the D42 autoreactive V region gene occurs between the T1 and T2 stages and is 
2–3 times more stringent in mice treated with a BAFF antagonist. Nevertheless, the light chain repertoire and 
clonal diversity of those D42 cells that escape deletion following BAFF inhibition is not substantially altered, 
and high-affinity autoreactive D42 B cells are still positively selected into the germinal center where they mature 
to autoreactive plasma cells (55). By contrast, B cells expressing the 3H9 autoreactive V region gene are deleted 
at the pre–B cell stage in the bone marrow with no additive effect of BAFF inhibition on the stringency of selec-
tion of naive 3H9 B cells that escape central deletion (16). There is a similar lack of effect of BAFF over- or 
underexpression on regulation of the autoreactive HKIR transgene, which is also regulated by central tolerance 
(56). BAFF inhibition has a modest effect on germinal center entry and proliferation of 3H9-positive autoreac-
tive B cells and on selection of the plasma cell repertoire; these effects vary between lupus strains (16). The effect 
of BAFF inhibition on selection of the human B cell repertoire has not been previously reported.
Next-generation sequencing (NGS) is a quantitative method to perform both cross-sectional and lon-
gitudinal analyses of  immunoglobulin repertoires and to identify expanded B cell clones. Here we used 
several analyses of  NGS data from belimumab-treated subjects to determine whether there might be loss 
of  autoreactive V region genes in the naive repertoire of  patients treated with belimumab. We first asked 
whether the normal pattern of  changes in VH gene usage observed at the transitional to naive checkpoint is 
exaggerated following belimumab therapy, suggesting more stringent negative selection. Although approxi-
mately 90% of  the naive B cell population is depleted following chronic belimumab therapy, we did not 
observe a redistribution of  V, D, or J family usage among unmutated IgM sequences from treated patients. 
Among VH genes, VH4-34 is associated with the anti-dsDNA response and its expression is increased dur-
ing disease activity. Nevertheless, the VH4-34 gene is frequently expressed in the naive repertoire both in 
healthy individuals and lupus patients (37), indicating that B cells expressing this gene are not regulated by 
central deletion or deletion at the transitional checkpoints. Consistent with this concept, we found no effect 
of  belimumab on the frequency of  VH4-34 among unmutated IgM sequences.
Table 1. Demographic characteristics of lupus patients and healthy donors
Lupus  
Controls Long-term Belimumab Initiating Belimumab Healthy Donors
 n = 17 n = 15 n = 5 n = 13
Age, mean years (SD) 45.4 (9.0) 47.3 (7.1) 39.2 (10.9) 39.2 (10.3)
Sex, n female (%) 17 (100%) 14 (93.3%) 5 (100%) 8 (61.5%)
Race, n (%)    
White 5 (29.4%) 5 (33.3%) 1 (20%) 2 (15.4%)
Black/African American or Afro Caribbean 6 (35.3%) 7 (46.7%) 3 (60%) 4 (30.8%)
Hispanic/Latino 3 (17.6%) 2 (13.3%) 1 (10%) 0 (0%)
Asian 2 (11.8%) 1 (6.7%) 0 (0%) 7 (53.8%)
SLE duration, mean years (SD) 9.5 (6.1)A 14.9 (4.1) 8 (3.5)
SELENA-SLEDAI, mean score (SD) 1.5 (1.8) 2.1 (2) 3.2 (3)
WBC × 106/cm3, mean (SD) 5.4 (1.7) 5.2 (2.3) 6.6 (3.2)
Lymphocytes × 106/cm3, mean (SD) 1.7 (0.6) 1.3 (0.5) 1.4 (0.2)
Anti-dsDNA negative <30 IU/ml n (%) 7/17 (41.2%) 7/15 (46.7%) 3/5 (60%)
Anti-dsDNA titer IU mean (SD) 224 (288.4) 89.7 (117.8) 138.8 (210)
C3 mean mg/dl (SD) 103 (28.3)B 120 (34.3)C 95.1 (27.8)D
C4 mean mg/dl (SD) 20 (10.4)B 25.2 (6.8)E 19.8 (9.3)D
Concomitant medications, n (%)    
Prednisone mg/day mean (SD) 0.6 (1.3)F 1.3 (3.9)G 13.8 (9.9)H,I
DMARDs n (%) 6/17 (35.3%)J 6/15 (40%)K 3/5 (60%)L
AP < 0.05 versus all belimumab treated. BHypocomplementemia in n = 3 (17.6%). CHypocomplementemia in n = 2 (13.3%). DHypocomplementemia in n = 
1 (20%). EHypocomplementemia in n = 0 (0%). FPrednisone in n = 4 (23.6%). GPrednisone in n = 3 (20%). HPrednisone in n = 5 (100%). IP < 0.0001 versus 
lupus control; P < 0.001 versus chronic belimumab. JMycophenolate, myfortic, methotrexate. KMycophenolate, azathioprine, methotrexate/leflunomide, 
dapsone, tacrolimus. LMycophenolate, azathioprine, methotrexate. SELENA-SLEDAI, Safety of Estrogens in Systemic Lupus Erythematosus National 
Assessment–SLE Disease Activity Index; DMARDs, disease-modifying antirheumatic drugs.
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The heavy chain CDR3 region makes a large contribution to the antigen binding site, and its composition 
is thought to be heavily influenced by selection events. Counterselection of  B cells containing VH genes with 
long hydrophobic CDR3s occurs during naive B cell selection and autoreactive B cells have been reported 
to contain longer, more hydrophobic heavy chain CDR3 regions than non-autoreactive B cells (40, 43). No 
differences in length or hydrophobicity of  CDR3s from the unmutated sequences were found between lupus 
controls and chronic belimumab–treated subjects, suggesting that BAFF availability does not further influence 
this aspect of  negative selection. Anti-dsDNA antibodies use heavy chain CDR3 regions with more basic and 
fewer acidic amino acids than non-autoreactive antibodies; our analyses did not detect selection against these 
characteristics in belimumab-treated subjects. These findings, in sum, confirm that although BAFF highly 
regulates survival of  naive B cells past the T1 stage in humans, we were unable to identify an effect of  beli-
mumab on selection of  the naive B cell repertoire. These data are consistent with a recent report showing no 
difference in the percentage of  naive anti–nuclear antigen–reactive (ANA-reactive) B cells identified by flow 
cytometry between belimumab-treated subjects and lupus controls (57).
Naive activated B cells from patients with active SLE are enriched in VH4-34 genes and can directly 
give rise to plasmablasts (29). In subjects treated with chronic belimumab, we found a significantly greater 
loss of  VH4-34 among mutated IgM sequences compared with unmutated sequences from the same sub-
jects, suggesting that BAFF inhibition promotes negative selection of  autoreactive activated naive B cells. 
VH4-34 is counterselected in the germinal center and plasma cell compartments of  healthy donors, but this 
counterselection fails in lupus (37). We found a significant loss of  VH4-34 in the plasmablast compartment 
of  chronic belimumab–treated subjects compared with the naive compartment of  the same patients, further 
confirming a potential role for BAFF inhibition in regulating activated B cells. Nevertheless, clonal expan-
sions of  mutated IgM sequences were observed in 2 chronic belimumab–treated patients, with matched 
expansions of  some of  these clones in the plasmablast compartment showing that belimumab does not 
prevent general clonal activation of  B cells.
Overall, our study indicates that BAFF regulates B cell survival at the T1 to T3 checkpoint in humans 
as it does in mice, resulting in greater than 90% depletion of  naive B cells and 60%–95% deletion of  all 
other B cell subsets after chronic treatment. We were unable to identify changes in the naive resting B cell 
VH or heavy chain CDR3 repertoire to suggest effects on the stringency of  negative selection of  this subset. 
By contrast, belimumab may promote negative selection of  autoreactive activated B cells and plasmablasts.
The strengths of  our study are the inclusion of  patients treated with belimumab for more than 7 years 
compared with closely matched lupus controls as well as patients studied longitudinally. We were able to 
perform careful phenotyping and to sample a large number of  naive B cells, class-switched and mutated 
CD27– cells and plasmablasts for repertoire analysis. There are, however, a number of  caveats to our study. 
First, we chose to analyze only the immunoglobulin heavy chain since this is responsible for most of  the 
differences in repertoire selection in normal individuals (34); however, we are missing information about 
the light chains, especially in the plasmablasts in which clonal expansions occur. Second, we are unable to 
distinguish whether a small number of  anergic cells might contribute to the repertoire of  surviving naive 
B cells in the belimumab-treated patients, as has been previously suggested (57). This would be of  interest 
to explore further since naive VH4-34–encoded B cells (9G4+ B cells) appear to be anergic both in healthy 
individuals and in lupus patients. Rescue of  these anergic cells by excess BAFF may be one mechanism by 
which abnormal activation and expansion of  VH4-34–encoded B cells is permitted in SLE patients (37). 
Restoration of  anergy could help explain the observed decrease in representation of  VH4-34 among acti-
vated B cell subsets in the belimumab-treated subjects reported here. Another potential mechanism would 
be a decrease in endosomal TLRs that drive activation and expansion of  autoreactive B cells and whose 
expression is enhanced by BAFF (7). It would be ideal to study the frequency of  autoreactive B cells in 
belimumab-treated patients before and after treatment by re-expressing the genes derived from single cells 
and testing for autospecificities; these studies are currently ongoing. Other affected functions of  the B cells 
that survive under conditions of  chronic BAFF depletion remain to be determined in future studies.
Methods
Human subjects. The following subjects were recruited to this investigator-initiated study: 15 SLE patients 
who had been continuously treated with 10 mg/kg belimumab monthly for more than 7 years as part of  
GSK-sponsored belimumab clinical studies; 17 SLE controls matched as closely as possible for disease 
activity, medications, gender, and ethnicity; and 13 healthy donors whose cells were used to set the gates for 
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the B cell phenotyping. Five SLE patients newly starting on belimumab were studied before and 6 months 
after drug initiation. One additional patient had samples available only at 0 and 2 months. Demographic 
characteristics of  SLE patients and controls are shown in Table 1.
Flow cytometry panels for B cell phenotype. Peripheral blood mononuclear cells (PBMCs) were stained 
with fluorophore-conjugated anti-human antibody cocktails in PBS/0.2% BSA/2 mM EDTA at 4°C for 30 
minutes (Supplemental Figure 1 and Supplemental Table 1). To distinguish naive from transitional cells, 
PBMCs were first loaded with 5 nM MitoTracker Green FM (Molecular Probes, Thermo Fisher Scientific) 
at 37°C for 30 minutes, washed, and then stained with the relevant antibody cocktail. Absolute B cell 
counts were calculated using lymphocyte counts and the B cell gate.
B cell VH library generation. Mature B cells were sorted as live CD3–CD11b–CD56–CD19+CD27–CD10–
CD43– cells. This sorting strategy included naive B cells, activated naive B cells, and DN cells that are thought 
to represent extrafollicularly activated B cells, but excluded transitional type 1 B cells that are not influenced 
by BAFF inhibition. Plasmablasts/plasma cells were sorted as live CD19loCD3–CD11b–CD56–CD19loCD-
27hiCD38hi cells (Supplemental Table 1) and are referred to throughout the manuscript as plasmablasts. Pellets 
were washed, and RNA was made using RNeasy (Qiagen) followed by PCR using a One-Step RT-PCR Kit 
(Qiagen). First-round VH primers HBHI-M 01-10 (iRepertoire) conferred a unique barcode from 1 to 10. A 
second round of  PCR was performed using a Qiagen Multiplex PCR Kit and communal primers (iReper-
toire). Gel bands corresponding to 490–570 bp were purified using a QIAquick Gel extraction Kit (Qiagen). 
Purified samples (120 ng of  each) were used to generate pooled libraries, each containing 10 individual librar-
ies marked with a different barcode. Pooled libraries were then sequenced using miSeq. Data were deposited 
into the NCBI’s Sequence Read Archive (SRA BioProject SAMN099549-601; https://www.ncbi.nlm.nih.
gov/Traces/study/?acc=SRP159206&go=go).
Analysis of  sequencing data. After initial filtering using iRepertoire algorithms, sequence data from 
mature B cells was filtered to separate IgM from non-IgM sequences. Unproductive sequences and/or 
sequences without identifiable CDR3 and/or D genes were filtered out using customized Perl and R scripts. 
Sequences were genotyped using IMGT High V-QUEST. IgM sequences with more than 3 mutations (29) 
were analyzed separately. Sequences with identical VH, DH, JH, and CDR3 were considered as a clone/
single cell. For mutated sequences, identical CDR3 length and CDR3 similarity of  greater than 85% were 
considered to define clonotype (29, 58).
Since antibody-secreting cells are highly mutated and contain high mRNA content, sequence data from 
the plasmablasts was filtered to exclude single-copy reads so as to minimize mutations introduced by PCR 
or sequencing. Customized Perl and R scripts were applied to filter out unproductive sequences and/or 
sequences without identifiable CDR3 and/or D genes. Sequences with identical VH, DH, JH, and CDR3 
length with greater than 85% CDR3 similarity were identified using alakazam and shazam packages from 
immcantation toolbox (https://immcantation.readthedocs.io) and considered as a clone.
Numbers of  sorted cells, sequence counts, and unique sequences at each step of  the filtering analysis 
are shown in Supplemental Table 2. After filtering, the number of  unique sequences recovered from each 
individual patient correlated closely with the starting number of  B cells.
CDR3 count, length, and amino acid frequencies were calculated using customized Perl and R scripts. 
The biophysical properties of  CDR3 were analyzed using R package (Peptides: kidera) to calculate Kidera 
factors (44) and a customized Perl script was used to calculate amino acid composition of  the CDR3 
sequences from each donor (Tiny = ACGST, Small = ACDGNPSTV, Aliphatic = AILV, Aromatic = 
FHWY, Non-polar = ACFGILMPVWY, Polar = DEHKNQRST, Charged = DEHKR, Basic = HKR, and 
Acidic = DE). Mean values of  the Kidera factors from each VH gene subfamily on CDR3 were calculated, 
and pricipal component analysis (PCA) plots were graphed using the prcomp R package. Figures were 
generated using either PRISM or R scripts using ggplot2 packages. Heatmaps were generated with log2-
transformed data (percentage of  usage) using the pheatmap package and unsupervised hierarchical cluster-
ing of  the 20 amino acids according to Euclidian distance.
Reference sequence data of  non-autoreactive and autoantigen-specific reactive antibodies. The heavy sequences 
of  445 non-autoreactive and 287 autoreactive B cells of  different specificities (ANA [n = 274], dsDNA [n 
= 124]) from early immature, immature, new immigrant, and mature naive B cells derived from 3 healthy 
subjects and 6 lupus patients were used as a reference repertoire (40, 41, 59).
Statistics. Comparisons in Figures 1 and 2, Table 1, and Supplemental Figures 3 and 6 were performed 
using 2-tailed Mann-Whitney analysis for 2-group comparisons or Kruskal-Wallis test for 3-group compari-
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sons. For 3-group problems, multiple comparisons were carried out using the the Dwass-Steel-Critchlow-
Fligner method. Paired comparisons in Figure 5 and Supplemental Figure 7 were performed using a 2-tailed 
Wilcoxon’s rank-sum test. Comparisons for VH repertoire analyses in Figures 3 and 4 and Supplemental 
Figures 4 and 6 were performed using a linear mixed model with main effects of  cell populations and treat-
ment groups as well as cell population × treatment groups interaction. Cell populations within subjects are 
the repeated factors. A P value less than 0.05 was considered statistically significant.
Study approval. The study was approved by the Feinstein Institute IRB and written informed consent 
was received from participants prior to inclusion in the study.
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